Copyright © 2004 by the European Society of Cardiology.
Review
Natriuretic peptides in unstable coronary artery disease
a Department of Medical Sciences, Cardiology and Uppsala Research Center, Sweden
b Department of Medical Sciences, Clinical Chemistry, Sweden
Received March 1, 2004; revised June 5, 2004; accepted June 10, 2004 * Corresponding author. Tel: +46-18-611-0232; fax: +46-18-50-66-38 (E-mail: tomas.jernberg{at}medsci.uu.se).
Patients with unstable coronary artery disease (CAD), i.e., unstable angina or non-ST-elevation myocardial infarction, vary widely in clinical presentation, prognosis and response to treatment. To select appropriate therapy, early risk stratification has become increasingly important. This review focuses on the emerging role of natriuretic peptides in the early assessment of patients with unstable CAD. We conclude that levels of brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are strongly associated to mortality and the risk of future congestive heart failure, and carry important prognostic information independent from previously known risk factors in unstable CAD. There are some data indicating that these markers can also be helpful in the selection of appropriate therapy in these patients but further studies are needed. Before a routine use of BNP or NT-proBNP in unstable CAD can be recommended, the cost-effectiveness of adding these new markers to the currently routine markers and their impact on selection of treatment needs further evaluation.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Weber, O. Bazzino, J. L. Navarro Estrada, J. J. Fuselli, F. Botto, D. Perez de Arenaza, H. Mollmann, H. N. Nef, A. Elsasser, and C. W. Hamm N-Terminal B-Type Natriuretic Peptide Assessment Provides Incremental Prognostic Information in Patients With Acute Coronary Syndromes and Normal Troponin T Values Upon Admission J. Am. Coll. Cardiol., March 25, 2008; 51(12): 1188 - 1195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kempf, E. Bjorklund, S. Olofsson, B. Lindahl, T. Allhoff, T. Peter, J. Tongers, K. C. Wollert, and L. Wallentin Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction Eur. Heart J., December 1, 2007; 28(23): 2858 - 2865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Wollert, T. Kempf, B. Lagerqvist, B. Lindahl, S. Olofsson, T. Allhoff, T. Peter, A. Siegbahn, P. Venge, H. Drexler, et al. Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non ST-Elevation Acute Coronary Syndrome Circulation, October 2, 2007; 116(14): 1540 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Ahmed, S. Zafar, A. Y. Alam, N. Ahktar, M. A. Shah, and M. A. Alpert Plasma Levels of B-Type Natriuretic Peptide in Patients With Unstable Angina Pectoris or Acute Myocardial Infarction: Prognostic Significance and Therapeutic Implications Angiology, June 1, 2007; 58(3): 269 - 274. [Abstract] [PDF]
|
|
|
|
|
|
G. Kwan, S. R. Isakson, J. Beede, P. Clopton, A. S. Maisel, and R. L. Fitzgerald Short-Term Serial Sampling of Natriuretic Peptides in Patients Presenting With Chest Pain J. Am. Coll. Cardiol., March 20, 2007; 49(11): 1186 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Wollert, T. Kempf, T. Peter, S. Olofsson, S. James, N. Johnston, B. Lindahl, R. Horn-Wichmann, G. Brabant, M. L. Simoons, et al. Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non-ST-Elevation Acute Coronary Syndrome Circulation, February 27, 2007; 115(8): 962 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Heart Protection Study Collaborative Group,* N-Terminal Pro-B-Type Natriuretic Peptide, Vascular Disease Risk, and Cholesterol Reduction Among 20,536 Patients in the MRC/BHF Heart Protection Study J. Am. Coll. Cardiol., January 23, 2007; 49(3): 311 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Rothenbacher, W. Koenig, and H. Brenner Comparison of N-Terminal Pro-B-Natriuretic Peptide, C-Reactive Protein, and Creatinine Clearance for Prognosis in Patients With Known Coronary Heart Disease Arch Intern Med, December 11, 2006; 166(22): 2455 - 2460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Laukkanen, S. Kurl, M. Ala-Kopsala, O. Vuolteenaho, H. Ruskoaho, K. Nyyssonen, and J. T. Salonen Plasma N-terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-aged men Eur. Heart J., May 2, 2006; 27(10): 1230 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Clerico, F. A. Recchia, C. Passino, and M. Emdin Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H17 - H29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Elsasser and C. W. Hamm Percutaneous coronary intervention guidelines: new aspects for the interventional treatment of acute coronary syndromes Eur. Heart J. Suppl., October 1, 2005; 7(suppl_K): K5 - K9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Dargie Heart failure post-myocardial infarction: a review of the issues Heart, May 1, 2005; 91(suppl_2): ii3 - ii6. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF]
|
|